RxDoctor Payments Data

Thomas Caves, MD

Gastroenterology · Santa Barbara, CANPI 1144284522

Payments from drug & device makers

$4,651in general payments, 2019–2025

Across 217 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$473
  • Johnson & Johnson$452
  • Pfizer$377
  • Takeda Pharmaceuticals U.S.A., Inc.$330
  • Madrigal Pharmaceuticals$273
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$4,55198%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,651 in reported general payments places this provider in the 60th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$238,094
Medicare patients
930
Services billed
3,891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide84$53,478
CreonLipase/Protease/Amylase17$21,943
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates303$19,473
MotegrityPrucalopride Succinate28$18,467
Mesalamine26$13,695
SutabSod Sulf/Pot Chloride/Mag Sulf44$6,893
Mesalamine ErMesalamine22$6,802
Pantoprazole Sodium535$5,392
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C32$4,635
VascepaIcosapent Ethyl12$4,213
Budesonide EcBudesonide31$3,407
Sucralfate39$3,204
Budesonide DrBudesonide17$2,293
CholestyramineCholestyramine (With Sugar)25$2,129
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg114$1,831

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,329$75,420101 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$330$18,46728 claims
Braintree Laboratories, Inc.Sutab$71$6,89344 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$473$4,63532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →